HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-World data shows HAE drugs effective in chinese patients
Disease control CompletedThis study looked at 115 Chinese patients with hereditary angioedema (HAE) to see how well two approved drugs work in everyday medical practice. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, is used to stop attacks once they start. Researchers count…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New shot could stop painful swelling attacks in kids with rare disease
Disease control CompletedThis study tested a monthly injection called Garadacimab to prevent swelling attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal was to see if the drug is safe and reduces how often attacks happen. 22 children took part, and researchers tracked side effect…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 10:34 UTC
-
New study offers free drug for rare swelling condition
Disease control CompletedThis study tested a drug called icatibant (Icanticure) in 5 adults with a rare condition that causes sudden, severe swelling (angioedema). The drug is already approved for hereditary angioedema, but this study aimed to provide it for free to patients who couldn't get it otherwise…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE4 • Sponsor: Nang Kuang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:31 UTC
-
Real-World data shows lanadelumab cuts HAE attacks over three years
Disease control CompletedThis study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab to see how well it works in real life. Participants reported their swelling attacks using a smartphone app and during routine doctor visits for up to three years. The main goal was…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Shire • Aim: Disease control
Last updated May 18, 2026 12:14 UTC
-
Real-world study tracks lanadelumab's attack control in HAE patients
Disease control CompletedThis study followed 48 people with hereditary angioedema (HAE) types I and II who were treated with lanadelumab through a Polish national drug program. Researchers tracked how many patients remained free of swelling attacks over 24 months, how many attacks required rescue medicat…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New data shows firazyr safe for kids with swelling attacks
Symptom relief CompletedThis study looked at the safety and effectiveness of the drug Firazyr (icatibant) in 32 children and teenagers (ages 2 to 17) with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Doctors gave the injection during an attack and watched for si…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Symptom relief
Last updated May 22, 2026 13:51 UTC
-
HAE patients and caregivers share real-world struggles in new survey
Knowledge-focused CompletedThis completed French survey studied the burden of on-demand treatment for hereditary angioedema (HAE) attacks from the perspective of 300 patients and their caregivers. It collected information on attack frequency, severity, treatment delays, and impacts on quality of life, soci…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated May 11, 2026 20:41 UTC